EAU 2017 - Prostate Cancer - Results from #7

Viewing 8-27 of 87 articles

EAU 2017: Multiparametric MRI represents an added value but not a substitute of follow-up biopsies in patients on active surveillance for low-risk prostate cancer

EAU 2017: Pathological findings at radical prostatectomy after initial active surveillance in low-risk prostate cancer patients. Did we miss the chance to cure?

EAU 2017: PTEN status in diagnostic biopsies predicts active surveillance rebiopsy Gleason upgrade, treatment change and adverse surgical histopathological findings

EAU 2017: Variation in the use of active surveillance for low-risk prostate cancer

EAU 2017: Metastases and death after 15 year of follow-up in men with screen-detected low-risk prostate cancer treated with protocol based active surveillance, radical prostatectomy or radiotherapy

EAU 2017: MRI as a follow up tool in active surveillance – results from an MRI-defined active surveillance cohort (387 men, median 5 year follow up)

EAU 2017: Risk-based selection for active surveillance: Results of the Movember Foundation’s Global Action Plan prostate cancer active surveillance (GAP3) initiative

EAU 2017: Variation in the use of active surveillance for low-risk prostate cancer

EAU 2017: State-of-the-art Lecture: EAU Guidelines on mCRPC – An Update

EAU 2017: Is There a Role for Local Treatment of Oligometastatic Disease? No

EAU 2017: Is There a Role for Local Treatment of Oligometastatic Disease? Yes

EAU 2017: State-of-the-art lecture Hereditary Prostate Cancer

EAU 2017: Active Surveillance for 3+4=7 Prostate Cancer - Pro

EAU 2017: Lessons from the ProtecT trial

EAU 2017: Con – mpMRI targeted biopsies are sufficient

EAU 2017: Con – Prostate Cancer Screening: Time to change recommendations for PSA testing

EAU 2017: Familial and genetic factors: New SNPs and panels

EAU 2017: Identification of a CTC-based prognostic signature in mCRPC driven by Aurora Kinase A and Wnt signaling Identification of a CTC-based prognostic signature in mCRPC driven by Aurora Kinase A and Wnt signaling

EAU 2017: A nomogram for prediction of local cancer recurrence after primary prostate cryoablation

EAU 2017: First repeated biopsy represents the most informative predictor of progression-free survival at 3 years follow-up in patients included in an active surveillance protocol for low-risk prostate cancer

1
2
3
4
5